Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TNFA promoter polymorphisms and narcolepsy.

S Wieczorek1, M Gencik, D Rujescu

  • 1Department of Human Genetics, Ruhr-University Bochum, MA5N/43, 44780 Bochum, Germany. stefan.wieczorek@ruhr-uni-bochum.de

Tissue Antigens
|June 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RFC1-related disorders: A case series of 4-aminopyridine and acetyl-DL-leucine treatment.

Cerebellum (London, England)·2026
Same author

Ketamine for negative and depressive symptoms in schizophrenia: the evidence so far.

Frontiers in psychiatry·2026
Same author

Human <i>in vivo</i> assessment of ketamine binding of the serotonin transporter-follow up at a higher dose.

Frontiers in neuroscience·2025
Same author

Genetic predisposition to unwanted side effects under antidepressants and antipsychotics: a molecular-genetic study of 902 patients over 6 weeks.

European archives of psychiatry and clinical neuroscience·2025
Same author

Contribution of Rare and Potentially Functionally Relevant Sequence Variants in Schizophrenia Risk-Locus Xq28,distal.

American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics·2024
Same author

Morphological correlates of anxiety-related experiences during a ketamine infusion.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry·2024
Same journal

Corrigendum.

Tissue antigens·2015
Same journal

Nomenclature for factors of the HLA system, update September 2015.

Tissue antigens·2015
Same journal

Nomenclature for factors of the HLA system, update August 2015.

Tissue antigens·2015
Same journal

Nomenclature for factors of the HLA system, update July 2015.

Tissue antigens·2015
Same journal

Four amino acid exchanges located in the alpha-2 domain specify the novel HLA-B*50:20 allele.

Tissue antigens·2015
Same journal

A novel HLA-A*02 variant, HLA-A*02:575, detected in a Taiwanese bone marrow hematopoietic stem cell donor.

Tissue antigens·2015
See all related articles

Genetic factors beyond HLA-DR2 influence narcolepsy risk. The study found a specific TNFA promoter polymorphism associated with narcolepsy in individuals without the HLA-DR2 type, suggesting genetic heterogeneity in the disorder.

Area of Science:

  • Neuroscience
  • Immunogenetics
  • Sleep Medicine

Background:

  • Narcolepsy is a sleep disorder with a strong genetic component, particularly associated with the HLA-DR2 antigen.
  • However, the HLA association alone does not fully explain familial risk, indicating other genetic factors are involved.
  • The TNFA gene, encoding the pro-inflammatory cytokine TNF-alpha, is located in the HLA class II region and its promoter polymorphisms are implicated in autoimmune diseases.

Purpose of the Study:

  • To investigate the potential etiological role of TNFA promoter polymorphisms in narcolepsy.
  • To explore whether TNFA alleles contribute to narcolepsy risk, especially in individuals lacking the HLA-DR2 association.
  • To examine genetic heterogeneity in narcolepsy based on HLA-DR2 status.

Main Methods:

Related Experiment Videos

  • Analysis of three single nucleotide polymorphisms (SNPs) in the TNFA promoter and one adjacent microsatellite.
  • Genotyping was performed on 103 narcolepsy patients and 96 healthy controls.
  • Statistical association analysis was conducted, stratifying by HLA-DR2 (specifically DRB1*15/16) status.

Main Results:

  • The T-allele of the TNFA C-857T polymorphism showed a significant association with narcolepsy.
  • This association was observed exclusively in the subgroup of patients negative for the DRB1*15/16 (HLA-DR2 type) haplotype.
  • No significant association was found in HLA-DR2 positive narcolepsy patients.

Conclusions:

  • TNFA promoter alleles, specifically the C-857T polymorphism, may play an etiological role in narcolepsy.
  • These findings support the concept of genetic heterogeneity in narcolepsy, with distinct pathophysiological pathways possibly existing in HLA-DR2 positive and negative individuals.
  • Further research into TNFA's role could elucidate novel therapeutic targets for narcolepsy subtypes.